The University of Chicago Header Logo

Connection

David A. Ehrmann to Humans

This is a "connection" page, showing publications David A. Ehrmann has written about Humans.
Connection Strength

0.611
  1. Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. Fertil Steril. 2022 05; 117(5):897-911.
    View in: PubMed
    Score: 0.027
  2. Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. Diabetologia. 2017 09; 60(9):1656-1661.
    View in: PubMed
    Score: 0.019
  3. Obstructive sleep apnea and polycystic ovary syndrome: cause or association? Sleep Med. 2017 08; 36:170-171.
    View in: PubMed
    Score: 0.018
  4. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016 10; 37(5):467-520.
    View in: PubMed
    Score: 0.018
  5. Hormonal Evaluation of Hyperandrogenism in Women. JAMA. 2015 Dec 15; 314(23):2557-8.
    View in: PubMed
    Score: 0.017
  6. Longitudinal relationship of diabetes-related distress and depressive symptoms: analysing incidence and persistence. Diabet Med. 2015 Oct; 32(10):1264-71.
    View in: PubMed
    Score: 0.017
  7. Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril. 2012 Jul; 98(1):242-9.
    View in: PubMed
    Score: 0.013
  8. Metabolic dysfunction in pcos: Relationship to obstructive sleep apnea. Steroids. 2012 Mar 10; 77(4):290-4.
    View in: PubMed
    Score: 0.013
  9. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod. 2011 Nov; 26(11):3138-46.
    View in: PubMed
    Score: 0.013
  10. Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011 Feb; 96(2):365-74.
    View in: PubMed
    Score: 0.012
  11. Sleep and metabolism. Preface. Best Pract Res Clin Endocrinol Metab. 2010 Oct; 24(5):vii-viii.
    View in: PubMed
    Score: 0.012
  12. Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab. 2010 Oct; 24(5):717-30.
    View in: PubMed
    Score: 0.012
  13. Variation in the perilipin gene (PLIN) affects glucose and lipid metabolism in non-Hispanic white women with and without polycystic ovary syndrome. Diabetes Res Clin Pract. 2009 Dec; 86(3):186-92.
    View in: PubMed
    Score: 0.011
  14. Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008 Oct; 93(10):3878-84.
    View in: PubMed
    Score: 0.010
  15. Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2008 Apr; 4(4):215-22.
    View in: PubMed
    Score: 0.010
  16. Pharmacologic therapy of polycystic ovary syndrome. Clin Obstet Gynecol. 2007 Mar; 50(1):244-54.
    View in: PubMed
    Score: 0.009
  17. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan; 91(1):48-53.
    View in: PubMed
    Score: 0.008
  18. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan; 91(1):36-42.
    View in: PubMed
    Score: 0.008
  19. Polycystic ovary syndrome. N Engl J Med. 2005 Mar 24; 352(12):1223-36.
    View in: PubMed
    Score: 0.008
  20. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Jan; 90(1):66-71.
    View in: PubMed
    Score: 0.008
  21. Letter to the Editor From Rosenfield, et al: "Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome". J Clin Endocrinol Metab. 2024 Sep 16; 109(10):e1962-e1963.
    View in: PubMed
    Score: 0.008
  22. Genetic contributions to glucose intolerance in polycystic ovary syndrome. Reprod Biomed Online. 2004 Jul; 9(1):28-34.
    View in: PubMed
    Score: 0.008
  23. Association of the (AU)AT-rich element polymorphism in PPP1R3 with hormonal and metabolic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2004 Jun; 89(6):2973-6.
    View in: PubMed
    Score: 0.008
  24. Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med. 2004 May-Jun; 66(3):356-62.
    View in: PubMed
    Score: 0.008
  25. Impaired beta-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2004 Aug; 287(2):E241-6.
    View in: PubMed
    Score: 0.007
  26. Pharmacologic treatment of polycystic ovary syndrome. Semin Reprod Med. 2003 Aug; 21(3):277-83.
    View in: PubMed
    Score: 0.007
  27. Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2002 Sep; 87(9):4297-300.
    View in: PubMed
    Score: 0.007
  28. Weight loss and ß-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial. Obesity (Silver Spring). 2022 08; 30(8):1579-1588.
    View in: PubMed
    Score: 0.007
  29. Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2002 Apr; 87(4):1669-73.
    View in: PubMed
    Score: 0.007
  30. Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose tolerance. Diabetologia. 2002 Apr; 45(4):509-17.
    View in: PubMed
    Score: 0.007
  31. Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab. 2002 Feb; 87(2):772-5.
    View in: PubMed
    Score: 0.007
  32. Insulin resistance and polycystic ovary syndrome. Curr Diab Rep. 2002 Feb; 2(1):71-6.
    View in: PubMed
    Score: 0.007
  33. Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2021 12; 44(12):2775-2782.
    View in: PubMed
    Score: 0.006
  34. Effect of Medical and Surgical Interventions on a-Cell Function in Dysglycemic Youth and Adults in the RISE Study. Diabetes Care. 2021 09; 44(9):1948-1960.
    View in: PubMed
    Score: 0.006
  35. Hyperglucagonemia Does Not Explain the ß-Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study. Diabetes Care. 2021 09; 44(9):1961-1969.
    View in: PubMed
    Score: 0.006
  36. Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study. Diabetes Care. 2021 09; 44(9):1938-1947.
    View in: PubMed
    Score: 0.006
  37. Liver Fat Reduction After Gastric Banding and Associations with Changes in Insulin Sensitivity and ß-Cell Function. Obesity (Silver Spring). 2021 07; 29(7):1155-1163.
    View in: PubMed
    Score: 0.006
  38. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab. 2001 May; 86(5):2027-31.
    View in: PubMed
    Score: 0.006
  39. Obstructive Sleep Apnea, Glucose Tolerance, and ß-Cell Function in Adults With Prediabetes or Untreated Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study. Diabetes Care. 2021 04; 44(4):993-1001.
    View in: PubMed
    Score: 0.006
  40. Withdrawal of medications leads to worsening of OGTT parameters in youth with impaired glucose tolerance or recently-diagnosed type 2 diabetes. Pediatr Diabetes. 2020 12; 21(8):1437-1446.
    View in: PubMed
    Score: 0.006
  41. Glucose intolerance in the polycystic ovary syndrome: role of the pancreatic beta-cell. J Pediatr Endocrinol Metab. 2000; 13 Suppl 5:1299-301.
    View in: PubMed
    Score: 0.006
  42. The association of sleep disturbances with glycemia and obesity in youth at risk for or with recently diagnosed type 2 diabetes. Pediatr Diabetes. 2019 12; 20(8):1056-1063.
    View in: PubMed
    Score: 0.006
  43. Association of Habitual Daily Physical Activity With Glucose Tolerance and ß-Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study. Diabetes Care. 2019 08; 42(8):1521-1529.
    View in: PubMed
    Score: 0.005
  44. Insulin-lowering therapeutic modalities for polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1999 Jun; 28(2):423-38, viii.
    View in: PubMed
    Score: 0.005
  45. Association of Self-Reported Sleep and Circadian Measures With Glycemia in Adults With Prediabetes or Recently Diagnosed Untreated Type 2 Diabetes. Diabetes Care. 2019 07; 42(7):1326-1332.
    View in: PubMed
    Score: 0.005
  46. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999 Jan; 22(1):141-6.
    View in: PubMed
    Score: 0.005
  47. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet. 2018 12; 14(12):e1007813.
    View in: PubMed
    Score: 0.005
  48. Attenuation of hyperinsulinemia in polycystic ovary syndrome: what are the options? J Endocrinol Invest. 1998 Oct; 21(9):632-5.
    View in: PubMed
    Score: 0.005
  49. Response to Letter to the Editor: "Androgens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Program". J Clin Endocrinol Metab. 2018 05 01; 103(5):2068.
    View in: PubMed
    Score: 0.005
  50. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018 04 01; 103(4):1233-1257.
    View in: PubMed
    Score: 0.005
  51. Androgens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2018 02 01; 103(2):486-496.
    View in: PubMed
    Score: 0.005
  52. Variation in Maturity-Onset Diabetes of the Young Genes Influence Response to Interventions for Diabetes Prevention. J Clin Endocrinol Metab. 2017 08 01; 102(8):2678-2689.
    View in: PubMed
    Score: 0.005
  53. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Jul; 82(7):2108-16.
    View in: PubMed
    Score: 0.005
  54. Review of methods for measuring ß-cell function: Design considerations from the Restoring Insulin Secretion (RISE) Consortium. Diabetes Obes Metab. 2018 01; 20(1):14-24.
    View in: PubMed
    Score: 0.005
  55. Long-term suppression of testosterone after treatment with a gonadotropin-releasing hormone agonist in a woman with a presumed testosterone secreting ovarian tumor. J Clin Endocrinol Metab. 1997 Jun; 82(6):1746-8.
    View in: PubMed
    Score: 0.005
  56. Relation of functional ovarian hyperandrogenism to non-insulin dependent diabetes mellitus. Baillieres Clin Obstet Gynaecol. 1997 Jun; 11(2):335-47.
    View in: PubMed
    Score: 0.005
  57. The effect of an education programme (MEDIAS 2 BSC) of non-intensive insulin treatment regimens for people with Type 2 diabetes: a randomized, multi-centre trial. Diabet Med. 2017 08; 34(8):1084-1091.
    View in: PubMed
    Score: 0.005
  58. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Feb; 82(2):524-30.
    View in: PubMed
    Score: 0.005
  59. Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants. Diabetes. 2016 Feb; 65(2):520-6.
    View in: PubMed
    Score: 0.004
  60. How to assess diabetes distress: comparison of the Problem Areas in Diabetes Scale (PAID) and the Diabetes Distress Scale (DDS). Diabet Med. 2016 06; 33(6):835-43.
    View in: PubMed
    Score: 0.004
  61. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun. 2015 Aug 18; 6:7502.
    View in: PubMed
    Score: 0.004
  62. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995 Jul; 96(1):520-7.
    View in: PubMed
    Score: 0.004
  63. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev. 1995 Jun; 16(3):322-53.
    View in: PubMed
    Score: 0.004
  64. Adolescent polycystic ovary syndrome due to functional ovarian hyperandrogenism persists into adulthood. J Clin Endocrinol Metab. 2015 Apr; 100(4):1537-43.
    View in: PubMed
    Score: 0.004
  65. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1994 Dec; 79(6):1686-92.
    View in: PubMed
    Score: 0.004
  66. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 Dec; 98(12):4565-92.
    View in: PubMed
    Score: 0.004
  67. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013 Dec; 98(12):4646-54.
    View in: PubMed
    Score: 0.004
  68. Interactions between pregnancy, obstructive sleep apnea, and gestational diabetes mellitus. J Clin Endocrinol Metab. 2013 Oct; 98(10):4195-202.
    View in: PubMed
    Score: 0.004
  69. Impaired insulin signaling in human adipocytes after experimental sleep restriction: a randomized, crossover study. Ann Intern Med. 2012 Oct 16; 157(8):549-57.
    View in: PubMed
    Score: 0.003
  70. Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med. 1992 Jul 16; 327(3):157-62.
    View in: PubMed
    Score: 0.003
  71. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J Clin Endocrinol Metab. 2012 Jul; 97(7):E1342-7.
    View in: PubMed
    Score: 0.003
  72. Sleep disturbances and their relationship to glucose tolerance in pregnancy. Diabetes Care. 2011 Nov; 34(11):2454-7.
    View in: PubMed
    Score: 0.003
  73. Hirsutism--beyond the steroidogenic block. N Engl J Med. 1990 Sep 27; 323(13):909-11.
    View in: PubMed
    Score: 0.003
  74. Clinical review 10: An endocrinologic approach to the patient with hirsutism. J Clin Endocrinol Metab. 1990 Jul; 71(1):1-4.
    View in: PubMed
    Score: 0.003
  75. Potential diagnostic utility of intermittent administration of short-acting gonadotropin-releasing hormone agonist in gonadotropin deficiency. Fertil Steril. 2010 Dec; 94(7):2697-702.
    View in: PubMed
    Score: 0.003
  76. Use of nafarelin for testing pituitary-ovarian function. J Reprod Med. 1989 Dec; 34(12 Suppl):1044-50.
    View in: PubMed
    Score: 0.003
  77. A new test of combined pituitary-testicular function using the gonadotropin-releasing hormone agonist nafarelin in the differentiation of gonadotropin deficiency from delayed puberty: pilot studies. J Clin Endocrinol Metab. 1989 Nov; 69(5):963-7.
    View in: PubMed
    Score: 0.003
  78. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med. 1989 Mar 02; 320(9):559-65.
    View in: PubMed
    Score: 0.003
  79. Characterization of functionally typical and atypical types of polycystic ovary syndrome. J Clin Endocrinol Metab. 2009 May; 94(5):1587-94.
    View in: PubMed
    Score: 0.003
  80. Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. J Clin Endocrinol Metab. 2009 May; 94(5):1579-86.
    View in: PubMed
    Score: 0.003
  81. The vital role of ORWH. Science. 2009 Feb 20; 323(5917):1009-10.
    View in: PubMed
    Score: 0.003
  82. Serum thyrotropin and the assessment of thyroid status. Ann Intern Med. 1989 Feb 01; 110(3):179-81.
    View in: PubMed
    Score: 0.003
  83. Limitations to the use of a sensitive assay for serum thyrotropin in the assessment of thyroid status. Arch Intern Med. 1989 Feb; 149(2):369-72.
    View in: PubMed
    Score: 0.003
  84. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008 Apr; 93(4):1105-20.
    View in: PubMed
    Score: 0.002
  85. Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci U S A. 2008 Jan 22; 105(3):1044-9.
    View in: PubMed
    Score: 0.002
  86. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes. 2007 Apr; 56(4):1153-9.
    View in: PubMed
    Score: 0.002
  87. Identification of a functional polymorphism of the human type 5 17beta-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan; 91(1):270-6.
    View in: PubMed
    Score: 0.002
  88. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005 Apr; 54(4):1150-6.
    View in: PubMed
    Score: 0.002
  89. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab. 2003 Dec; 88(12):6115; author reply 6115-6.
    View in: PubMed
    Score: 0.002
  90. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab. 2003 Nov; 88(11):5137-44.
    View in: PubMed
    Score: 0.002
  91. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril. 2003 Apr; 79(4):932-7.
    View in: PubMed
    Score: 0.002
  92. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001 Apr; 86(4):1626-32.
    View in: PubMed
    Score: 0.002
  93. Quantitative indexes of beta-cell function during graded up&down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab. 2001 Jan; 280(1):E2-10.
    View in: PubMed
    Score: 0.002
  94. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest. 2000 Aug; 106(3):329-33.
    View in: PubMed
    Score: 0.001
  95. Diagnosis of the polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism. J Pediatr Endocrinol Metab. 2000; 13 Suppl 5:1285-9.
    View in: PubMed
    Score: 0.001
  96. Transmission ratio distortion at the INS-IGF2 VNTR. Nat Genet. 1999 Aug; 22(4):324-5.
    View in: PubMed
    Score: 0.001
  97. Molecular analysis of the gonadotropin-releasing hormone receptor in patients with polycystic ovary syndrome. Fertil Steril. 1999 Aug; 72(2):360-3.
    View in: PubMed
    Score: 0.001
  98. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A. 1999 Jul 20; 96(15):8573-8.
    View in: PubMed
    Score: 0.001
  99. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest. 1997 Aug 01; 100(3):530-7.
    View in: PubMed
    Score: 0.001
  100. Acute hormonal responses to the gonadotropin releasing hormone agonist leuprolide: dose-response studies and comparison to nafarelin--a clinical research center study. J Clin Endocrinol Metab. 1996 Sep; 81(9):3408-11.
    View in: PubMed
    Score: 0.001
  101. The GENNID Study. A resource for mapping the genes that cause NIDDM. Diabetes Care. 1996 Aug; 19(8):864-72.
    View in: PubMed
    Score: 0.001
  102. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab. 1994 Nov; 79(5):1328-33.
    View in: PubMed
    Score: 0.001
  103. Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism. Ann N Y Acad Sci. 1993 May 28; 687:162-81.
    View in: PubMed
    Score: 0.001
  104. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1993 May; 76(5):1241-7.
    View in: PubMed
    Score: 0.001
  105. Ovarian steroidogenic responses to gonadotropin-releasing hormone agonist testing with nafarelin in hirsute women with adrenal responses to adrenocorticotropin suggestive of 3 beta-hydroxy-delta 5-steroid dehydrogenase deficiency. J Clin Endocrinol Metab. 1993 Feb; 76(2):450-5.
    View in: PubMed
    Score: 0.001
  106. Maturation of gonadotropin and sex steroid responses to gonadotropin-releasing hormone agonist in males. J Clin Endocrinol Metab. 1993 Feb; 76(2):362-6.
    View in: PubMed
    Score: 0.001
  107. Adrenal localization in the adrenocorticotropic hormone-independent Cushing syndrome. Ann Intern Med. 1988 Oct 01; 109(7):547-53.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.